Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP359223.RAGIRMjHC9q3OkC79GBW6lUR-hDNaJUXMcKMQ4u4t5oIA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP359223.RAGIRMjHC9q3OkC79GBW6lUR-hDNaJUXMcKMQ4u4t5oIA130_assertion type Assertion NP359223.RAGIRMjHC9q3OkC79GBW6lUR-hDNaJUXMcKMQ4u4t5oIA130_head.
- NP359223.RAGIRMjHC9q3OkC79GBW6lUR-hDNaJUXMcKMQ4u4t5oIA130_assertion wasGeneratedBy ECO_0000203 NP359223.RAGIRMjHC9q3OkC79GBW6lUR-hDNaJUXMcKMQ4u4t5oIA130_provenance.
- NP359223.RAGIRMjHC9q3OkC79GBW6lUR-hDNaJUXMcKMQ4u4t5oIA130_assertion wasDerivedFrom befree-2016 NP359223.RAGIRMjHC9q3OkC79GBW6lUR-hDNaJUXMcKMQ4u4t5oIA130_provenance.
- NP359223.RAGIRMjHC9q3OkC79GBW6lUR-hDNaJUXMcKMQ4u4t5oIA130_assertion SIO_000772 12091121 NP359223.RAGIRMjHC9q3OkC79GBW6lUR-hDNaJUXMcKMQ4u4t5oIA130_provenance.
- NP359223.RAGIRMjHC9q3OkC79GBW6lUR-hDNaJUXMcKMQ4u4t5oIA130_assertion evidence source_evidence_literature NP359223.RAGIRMjHC9q3OkC79GBW6lUR-hDNaJUXMcKMQ4u4t5oIA130_provenance.
- NP359223.RAGIRMjHC9q3OkC79GBW6lUR-hDNaJUXMcKMQ4u4t5oIA130_assertion description "[This protective effect mediated by the presence of GSTM1 was even more pronounced within the subset of therapy group B patients at highest clinical risk of treatment failure (B-ALL, disease stage IV, disease stage III with unresected abdominal tumor, and LDH activity > or = 500 U/L).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP359223.RAGIRMjHC9q3OkC79GBW6lUR-hDNaJUXMcKMQ4u4t5oIA130_provenance.